Merck announced that the European Commission has approved ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower‑respiratory‑tract disease in neonates and infants during their first RSV season. The approval covers the 27 EU member states plus Iceland, Liechtenstein and Norway and removes a regulatory hurdle that had delayed the drug’s launch in Europe.
ENFLONSIA is a long‑acting monoclonal antibody that delivers rapid, durable protection for five months with a single, non‑weight‑based dose of 105 mg. The approval is backed by data from the CLEVER and SMART trials, which showed a 60.4 % reduction in RSV‑associated medically attended lower‑respiratory infections and an 84.2 % reduction in RSV‑associated hospitalizations compared with placebo.
The European Commission’s approval follows the U.S. FDA’s approval of ENFLONSIA on June 10 2025, marking the first time the drug has received regulatory clearance in both major markets. The decision removes a key regulatory barrier that had delayed the product’s European launch and positions Merck to enter the RSV preventive market in the region.
ENFLONSIA is the first and only RSV preventive option available in the EU, giving Merck a competitive edge against existing therapies such as palivizumab and the newer long‑acting antibody Beyfortus (nirsevimab). The approval also supports Merck’s broader strategy to diversify beyond its oncology‑centric portfolio, leveraging its recent acquisitions and pipeline expansion to capture growth in the infant‑health segment.
Merck’s Q4 2025 results, released on February 3 2026, reported worldwide sales of $65.0 billion and GAAP earnings per share of $7.28. The company guided full‑year 2026 worldwide sales to $65.5 billion–$67.0 billion, indicating confidence in continued growth. The ENFLONSIA launch is expected to contribute to this trajectory by opening a new revenue stream in a high‑need therapeutic area.
ENFLONSIA will be available in all covered European markets, with distribution expected to begin shortly after the approval. The drug’s single‑dose, five‑month protection profile and non‑weight‑based dosing are expected to drive adoption among clinicians and parents, potentially capturing a significant share of the RSV preventive market as the product becomes widely available.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.